CreativeOne Wealth LLC Acquires New Shares in Insulet Co. (NASDAQ:PODD)

CreativeOne Wealth LLC purchased a new stake in Insulet Co. (NASDAQ:PODD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 887 shares of the medical instruments supplier’s stock, valued at approximately $206,000.

Several other large investors have also recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its holdings in Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after purchasing an additional 47 shares during the period. Avestar Capital LLC bought a new stake in shares of Insulet during the 3rd quarter worth $223,000. Brooklyn Investment Group bought a new stake in shares of Insulet during the 3rd quarter worth $167,000. Bank of Montreal Can lifted its holdings in shares of Insulet by 9.0% during the 3rd quarter. Bank of Montreal Can now owns 120,701 shares of the medical instruments supplier’s stock worth $28,006,000 after acquiring an additional 9,991 shares during the last quarter. Finally, Independent Advisor Alliance bought a new stake in shares of Insulet during the 3rd quarter worth $266,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PODD. BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Morgan Stanley lifted their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Canaccord Genuity Group lifted their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price on the stock. Finally, UBS Group boosted their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Trading Up 1.2 %

Shares of NASDAQ PODD opened at $269.66 on Wednesday. The firm’s 50 day moving average price is $244.95 and its 200-day moving average price is $214.95. The company has a market cap of $18.91 billion, a PE ratio of 46.17, a P/E/G ratio of 4.07 and a beta of 1.21. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.